Goldman Sachs maintains a Neutral rating on NASDAQ:TGTX and raises the price target from $37 to$39.TG Therapeutics projects significant revenue growth, expecting FY25 revenue to reach approximately $616 million, an 87$875 million and $900 million.BRIUMVI, the company's flagship product, is anticipated to generate substantial product revenue, contributing around$594 million in FY25 and between $825 million and$850 million in FY26.TG Therapeutics, Inc. (NASDAQ:TGTX) is ...